Fairvalue-Calculator Fairvalue-Calculator
EN DE

NIBEC Co (138610) Fair Value & Analysis

Healthcare · KR · Market cap 221B KRW

Price17,310 KRW
Fair Value13,454 KRW
Upside-22.3%
Quality95/100
Evidence: High Range 6,773 KRW – 17,642 KRW

Fair value as of: Jun 24, 2026

Analysis

NIBEC Co (138610) currently trades at 17,310 KRW, while our model-based Fair Value estimate is 13,454 KRW — implying the stock looks roughly 22.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

NIBEC Co., Ltd., a healthcare company, engages in the manufacture and sale of dental bone grafts and tissue regenerative collagen products in South Korea and internationally. It offers dental ointment, peptide containing dental bone graft materials, regenerative biomaterials, tooth whitening, tooth desensitizer, herbal toothpaste, and cosmetic products. The company was founded in 2000 and is based in Jincheon-eup, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is NIBEC Co (138610) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 13,454 KRW versus a price of 17,310 KRW — about −22% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 138610?
Our 21-model fair value for NIBEC Co is 13,454 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 17,310 KRW.
What is the quality score of 138610?
NIBEC Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.